

Research article

Open Access

Tumor-derived Matrix Metalloproteinase-13 (MMP-13) correlates with poor prognoses of invasive breast cancer

Bin Zhang^{†1,2}, Xuchen Cao^{†1,2}, Yanxue Liu³, Wenfeng Cao³, Fei Zhang¹, Shiwu Zhang³, Hongtao Li^{1,2}, Liansheng Ning^{1,2}, Li Fu^{1,4}, Yun Niu^{1,4}, Ruifang Niu¹, Baocun Sun^{1,3} and Xishan Hao^{*1}

Address: ¹National Key Laboratory of Breast Cancer Prevention and Treatment, Tianjin Medical University Cancer Institute and Hospital (TJMUCIH), Tianjin, P.R.China, ²Department of Breast Cancer Surgery, Tianjin Medical University Cancer Institute and Hospital (TJMUCIH), Tianjin, P.R.China, ³Department of Pathology, Tianjin Medical University Cancer Institute and Hospital (TJMUCIH), Tianjin, P.R.China and ⁴Department of Breast Cancer Pathology, Tianjin Medical University Cancer Institute and Hospital (TJMUCIH), Tianjin, P.R.China

Email: Bin Zhang - eeflying@163.com; Xuchen Cao - cxc111111@sohu.com; Yanxue Liu - dr_liuyanxue@163.com; Wenfeng Cao - caowenfeng@yahoo.com.cn; Fei Zhang - dr_zhangfei@163.com; Shiwu Zhang - Dr_zhangshiwu@163.com; Hongtao Li - dr_lihongtao@163.com; Liansheng Ning - dr_ningsheng@163.com; Li Fu - dr_fuli@163.com; Yun Niu - dr_niuyun@163.com; Ruifang Niu - niurf@eyou.com; Baocun Sun - dr_sunbaocun@163.com; Xishan Hao* - eeflying@163.com

* Corresponding author †Equal contributors

Published: 28 March 2008

Received: 16 September 2007

BMC Cancer 2008, 8:83 doi:10.1186/1471-2407-8-83

Accepted: 28 March 2008

This article is available from: <http://www.biomedcentral.com/1471-2407/8/83>

© 2008 Zhang et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Experimental evidence suggests that matrix metalloproteinase-13 (MMP-13) protein may promote breast tumor progression. However, its relevance to the progression of human breast cancer is yet to be established. Furthermore, it is not clear whether MMP-13 can be used as an independent breast cancer biomarker. This study was conducted to assess the expression profile of MMP-13 protein in invasive breast carcinomas to determine its diagnostic and prognostic significance, as well as its correlation with other biomarkers including estrogen receptor (ER), progesterone receptor (PR), Her-2/neu, MMP-2, MMP-9, tissue inhibitor of MMP-1 and -2 (TIMP-1 and TIMP-2).

Methods: Immunohistochemistry (IHC) was performed on paraffin-embedded tissue microarray containing specimens from 263 breast carcinomas. The intensity and the extent of IHC were scored by pathologists in blind fashion. The correlation of the gene expression profiles with patients' clinicopathological features and clinical outcomes were analyzed for statistical significance.

Results: MMP-13 protein was detected in the cytoplasm of the malignant cells and the peritumoral stromal cells. MMP-13 expression by tumor cells ($p < 0.001$) and stromal fibroblasts ($p < 0.001$) both correlated with carcinoma infiltration of lymph nodes. MMP-13 also correlated with the expression of Her-2/neu ($p = 0.015$) and TIMP-1 ($p < 0.010$), respectively in tumor cells. Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor phenotypes. Moreover, high levels of MMP-13 expression were associated with decreased overall survival. In parallel, the prognostic value of MMP-13 expressed by peritumoral fibroblasts seems less significant. Our data suggest that lymph node status, tumor size, Her-2/neu expression, TIMP-1 and MMP-13 expression in cancer cells are independent prognostic factors.

Conclusion: Tumor-derived, but not stromal fibroblast-derived, MMP-13 correlated with aggressive tumor phenotypes, and inversely correlated with the overall survival of breast cancer patients. MMP-13 may serve as an independent prognostic factor for invasive breast cancer patients. MMP-13 may be particularly useful as a prognostic marker when evaluated along with Her-2/neu and lymph node status.

Background

Breast cancer is one of the leading causes of cancer death among women worldwide. Of particular significance, the incidence and mortality rate of breast cancer increased sharply in China over the last couple of decades [1]. Clinical parameters, such as the size of the primary tumor, the histological grade, and regional lymph node involvement, are generally useful for predicting the prognosis. However, the profile of molecular markers may provide valuable insights into the underlying mechanisms of disease progression, thus aiding the intervention strategies. In light of the racial disparities of breast cancer incidences and prognoses documented in the literature, it is important to identify and validate specific biomarkers for Chinese breast cancer patients. To this end, estrogen receptor (ER)/progesterone receptor (PR), and oncogene Her-2/neu have been shown to be useful markers of breast cancer [2,3].

Breast cancer mortality derives overwhelmingly from invasion and metastasis, a process that requires continuous and extensive remodeling of tumor stroma. Epithelial basement membrane and extracellular matrix (ECM) are composed of tough network of fibrillar ECM proteins that can be directly degraded only by divalent cation-dependent matrix metalloproteinases (MMPs). Not surprisingly, experimental evidence supports a critical role of MMPs, such as MMP-2 and MMP-9, in the invasion and metastasis of breast cancer [4]. MMP-13, also named collagenase-3, is another MMP that is implicated in the degradation of ECM [5,6]. Recent studies further suggests that MMP-13 may play a central role in the extracellular MMP activation cascade [7,8]. It has been reported that overexpression of MMP-13 in several types of malignancy [9-17] is associated with shorter overall survival of the patients [16,18,19]. Consistently, functional evidence demonstrates that MMP-13 increases the invasive capacities of the malignant cells [20-24]. Interestingly, the clinical utility of MMP-13 as a breast cancer marker remains controversial. While several studies conclude that MMP-13 is produced by tumor stromal fibroblast-like cells [5], others claim that MMP-13 is synthesized predominantly by tumor cells [25]. For example, Balduyck, et al, demonstrated that MMP-13 was expressed in more invasive breast carcinoma cells [21]. Nielsen and colleagues showed that MMP-13 was expressed in myofibroblasts [25,26].

The goal of current study was to evaluate the prognostic values of MMP-13 expression level and its tissue distribution pattern in a large cohort of human breast cancer patients. Our evidence demonstrates that increased tumor-derived MMP-13 expression independently predicts poor prognoses. Furthermore, the combination of

MMP-3 with other clinicopathological parameters and/or other breast cancer biomarkers may be particularly useful.

Methods

Human subjects and tissue specimens

The cohort includes a total of 263 cases of invasive breast cancer, diagnosed and surgically treated between January and December 1993 at the Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital [27]. Patients had not received prior radiotherapy or neoadjuvant therapies. All patients received conventional postoperative treatments, depending on the extents of the disease. Patients without axillary lymph node involvement were treated with operation alone, while patients with axillary lymph node involvement received six courses of adjuvant chemotherapy with cyclophosphamide/methotrexate/fluorouracil regiment. Patients with positive nodes or tumor size ≥ 5 cm received postoperative radiation. The patients with ER+/PR+ tumor were treated for 2-5 years with tamoxifen.

The patient characteristics including age (median: 50.3 years), menopausal status, clinical stage (TNM classification defined by the International Union against Cancer, UICC, 2003) were assessed by the surgical pathologists. These data as well as the postoperative follow-up information including local (regional) recurrence and overall survival have been previously described [27]. Briefly, among the 263 cases, 132 women were premenopausal, while 131 were postmenopausal. At the time of operation, 68 cases (25.9%) were Grade I tumors, 119 (45.25%) cases were grade II tumors, and 76 cases (28.90%) were grade III tumors. We used the commonly used grading standard to assign the scores of histological grades of breast cancer. Briefly, the tumor grading combines nuclear grade, tubule formation and mitotic rate. Grade I is assigned to well-differentiated tumors. Grade II is assigned to moderately differentiated tumors. Grade III is assigned to poorly differentiated tumors. Among the 263 cases, 45 cases (17.1%) were classified of T1, 154 cases (58.6%) were T2, 59 cases (22.4%) were T3 and 5 (1.9%) cases were T4. A total of 128 cases (48.%) were lymph node negative, 57 cases (21.7%) were N1, 26 cases (9.9%) were N2, and 52 case (19.8%) were N3. Local recurrence happened in 8 cases (3%). Metastases were identified in 54 cases (20.5%), including 13 cases to the liver, 12 cases to the bone, 11 cases to the lung, 7 cases to ipsilateral or the contralateral suprascapular lymph nodes, 5 cases to the contralateral breast, 2 cases to the brain, 2 cases to the ovary, 1 case to the pericardium, and 1 case to the pleura. All patients, unless deceased, were followed up for at least 36 months, up to 173 months. The cases lost (due to patients' death or other reasons) for follow-up had been marked as censored data. Patient outcome was defined by the months of post surgery overall survival (OS). This study

was performed under a protocol approved by the Tianjin Medical University Administrative Panel on Human Subjects in Medical Research and the Institutional Review Boards of Tianjin Cancer Research institution.

Tissue microarrays (TMA) and immunohistochemistry (IHC)

TMA were constructed with a Beecher Instruments Tissue Array (Beecher Instruments, Silver Spring, MD) as previously described [27]. Briefly, archival paraffin blocks of invasive breast cancer cases. The recipient blocks were cut into tissue cores of 0.6 mm in diameter. Two cores of each specimen, representing the tumor areas, are transferred to the donor blocks.

Consecutive 4 μ m-thick sections were cut from the recipient blocks to a poly-L-lysine-coated slide for IHC analysis. IHC was performed using a method as described previously [27]. A modification of antigen retrieval (5 min high-power microwave followed by 10 min low-power microwave in phosphate-buffered saline (PBS, PH 7.0) was made for detecting MMP-2, MMP-9, MMP-13, TIMP-1 and TIMP-2. The antibodies and the dilution factors were as follows: MMP-13 (1: 150 diluted Clone VIIIA2 from Lab Vision Corp.), ER (1:450 diluted clone ID5 from DAKO), PR (1:200 diluted clone IA6 from DAKO); Her2/neu (1:1000 diluted polyconal from DAKO), MMP-2 (1:150 diluted polyclonal from Lab Vision Corp), MMP-9 (1:150 diluted polyclonal from Lab Vision Corp), TIMP-1 (1:150 diluted polyclonal from Lab Vision Corp), and TIMP-2 (1:150 diluted polyclonal from Lab Vision Corp).

Human placenta tissue known to express high levels of MMP-2, MMP-9 TIMP-1 and TIMP-2 [28,29] were used as positive controls for these proteins, respectively. Breast cancer cell lines MCF-7 and T47D were used as positive control for ER and PR, respectively. Ovarian cancer cell line SK-OV-3 was used as a positive control for Her-2/neu staining [30]. PBS was used in the place of the primary antibodies in all negative controls of IHC.

Semi-quantitative measurement of immunostaining

IHC was scored independently using a semi-quantitative scoring system as described below by two pathologists (WC and YL), who were both blinded to patients' clinicopathologic parameters and outcomes. Discordant scores were re-evaluated by the investigators and the consensus scores were used for further analyses. Both the intensity and extent of IHC were assessed [27]. The intensity of the immunostaining was defined by the negative and positive controls as four categories. No brown particle staining: 0; light brown particle in cytoplasm: 1; moderate brown particle: 2; and 3: dark brown particle. The percentage of positive cells, as the extent of immunostaining, was quantified under microscope and classified into four groups. 1: <25% positive cells; 2: 25% to 50% positive

cells; 3, 51% to 75% positive cells and 4, >75% positive cells. The staining index (SI), the product of the intensity and the percentage of positive staining, was used to define high ($SI \geq 6$) or low ($SI < 6$) expression of MMP-13, MMP-2, MMP-9, TIMP-1 and TIMP-2.

The criterion of Herceptest/Pathway system was followed to score Her-2/neu. Briefly, cases with strong complete membranous staining in more than 10% of the tumor cells were considered strongly positive (+3). Cases with weak to moderate complete membranous staining in more than 10% of the tumor cells were considered moderately positive (+2) and were subsequently confirmed by fluorescence *in situ* hybridization. Cases with little or no membranous staining were considered negative (0 or +1) [31]. The criteria for scoring of ER and PR are similar. Cases with strong/moderate complete nuclear staining in more than 15% of the tumor cells were considered positive, whereas cases with little or no nuclear staining were considered negative [27,31].

Statistical analysis

Statistical analyses were performed using the SPSS software package 11.0 (SPSS, Inc. Chicago, IL, USA). The correlations between MMP-13 expression and clinicopathologic variables were analyzed using Pearson Chi-square analysis. The same method was used to test the associations of MMP-13 with ER, PR, and Her-2/neu, respectively. Kaplan-Meier curves were constructed for univariate and multivariate analyses using a Cox proportional hazards model to examine the potential prognostic variables on OS. No corrections for multiple comparisons were made. All of the statistical tests were two-sided. *p* values of less than 0.05 were considered statistically significant.

Results

Breast cancer cells and peritumoral fibroblasts both express MMP-13

Distinct IHC staining of MMP-13 was obtained from all 263 cases. The tumor or fibroblast-specific staining was semi-quantitatively scored by the SI scales and assigned into high and low categories. As shown in Figure 1, MMP-13 protein expression was detected mainly in cytoplasm of malignant cells and the peritumoral fibroblasts in 127 (48.29%) and 144 (54.75%) cases, respectively. One hundred and eleven out of 127 specimens with high levels of tumor expression of MMP-13 (87.40%) featured high levels of MMP-13 in peritumoral fibroblasts. Consistently, 106 out of 144 specimens with low levels of tumor expression of MMP-13 were accompanied by peritumoral fibroblasts that expressed MMP-13 at low levels (Table 1). Overall, the detection of cytoplasmic MMP-13 in tumor cells, correlated significantly with the cytoplasmic MMP-13 in the peritumoral fibroblasts ($p < 0.0001$).




Figure 1
Differential expression of MMP-13 in breast cancer and peritumoral fibroblast cells. Invasive ductal carcinoma featured MMP-13 protein in the cytoplasm of both the cancer cells and peritumoral fibroblast cells (A). High levels of MMP-13 protein exclusively in the cytoplasm of the cancer cells (B). The brown color represents the IHC staining of MMP-13. The blue color represents the nuclear counterstain. × 400. Insets of A and B show a section of the each field with higher magnification. × 1000.

MMP-13 correlates with lymph node infiltration and Her-2/neu expression

To test the potential value of MMP-13 as a breast cancer biomarker, we performed Pearson Chi-square analysis to evaluate the correlation of MMP-13 expression with clinical and histopathological features (tumor size, tumor grade, and lymph node status) that are further stratified as shown in Table 2. *p* values of less than 0.05 was considered statistically significant. High levels of MMP-13 expression, both in cancer cells and in peritumoral fibroblasts, correlated with lymph node metastases (*p* < 0.001), but not with tumor size and histological grade. MMP-13 did not appear to be regulated by sexual steroid hormones, since it was not correlated with the menopausal statuses of the patients. Nor was it correlated with ER or PR. Interestingly, a strong correlation between MMP-13, both in cancer cells (*p* = 0.015) and peritumoral fibro-

lasts (*p* < 0.001), was observed with Her-2/neu nuclear staining.

MMP-13 correlated with TIMPs, but not with MMP-2 and MMP-9

Biochemically redundant members of the MMP family may have intricate interplay in tumor progression. To begin to understand the relative significance of MMP-13, we examined its correlation with other MMPs (MMP-2 and MMP-9) and tissue inhibitors of MMP (TIMP-1 and TIMP-2). Distinct IHC staining of each of these proteins were detected in the cytoplasm of both the cancer cells and adjacent fibroblasts (Figure 2). MMP-13 detected either in cancer cells or in adjacent fibroblasts, was not correlated with MMP-2 or MMP-9 (Table 2). Thus, the differential expression of MMP-13 in breast tumor progression may be regulated by a mechanism different from those for MMP-2 and MMP-9. High levels of MMP-13 in both cancer cells (*p* < 0.010) and peritumoral fibroblasts (*p* = 0.002), significantly correlated with the levels of TIMP-1 protein in the same specimens. In addition, MMP-13 in peritumoral fibroblasts correlated to lesser extent, albeit significant, with the levels of TIMP-2 protein (*p* = 0.029).

MMP-13 negatively correlates with breast cancer OS

The mean follow-up of the 263 patients in our cohort is 92.1 months. Kaplan-Meier analyses showed a clear stratification of the OS between the patients with high levels of MMP-13 expression and the patients with low levels of MMP-13 expression (Table 3). High levels of MMP-13

Table 1: Correlation of tumor-derived MMP-13 with stromal fibroblast-derived MMP-13

		Stromal Fibroblast-derived MMP-13				<i>p</i>	<i>R</i>
		Low		High			
		n	%	n	%		
Tumor-derived MMP-13	Low	103	75.7	33	24.3	< 0.001	0.634
	High	16	12.6	111	87.4		

Low: immunostaining SI < 6; High immunostaining SI > 6; n: number of the cases

Table 2: Correlation of high MMP-13 expression with clinicopathological parameters and other biomarkers

Parameters/Markers	Total	High MMP-13 expression					
		Cancer Cells		<i>p</i>	Stromal Fibroblasts		
		<i>n</i>	%			<i>n</i>	%
Menopausal							
Pre-menopausal	132	64	48.5	0.949	70	53.0	0.573
Post-menopausal	131	63	48.1		71	56.5	
Tumor Size							
<2 cm	46	25	54.3	0.365	28	60.9	0.359
>2 cm	217	102	47.0		116	53.5	
Lymph Node Status							
N0	128	43	33.6	< 0.001	55	43	< 0.001
N1	57	25	43.9		31	54.4	
N2	26	17	65.4		16	61.5	
N3	52	42	80.8		42	80.8	
Histological Grade							
G1	68	22	32.35	0.001	27	39.7	0.071
G2	119	56	47.06		67	56.3	
G3	76	49	64.47		51	54.8	
ER Status							
Negative	101	51	50.5	0.572	56	55.4	0.859
Positive	162	76	46.9		88	54.3	
PR Status							
Negative	101	85	52.5	0.086	95	58.6	0.109
Positive	162	42	41.6		49	48.5	
HER2/neu Protein							
Negative	211	94	44.5	0.0150	101	47.9	< 0.001
Positive	52	33	63.5		43	82.7	
MMP-2 Protein							
Negative	171	81	47.4	0.234	96	56.1	0.927
Positive	51	29	56.9		29	56.9	
MMP-9 Protein							
Negative	162	88	54.3	0.911	81	50.0	0.367
Positive	58	32	55.2		42	43.3	
TIMP-1 expression							
Negative	131	50	38.2	< 0.001	63	48.8	0.002
Positive	72	52	72.2		51	70.8	
TIMP-2 Protein							
Negative	41	15	36.6	0.080	52	35.6	0.029
Positive	142	74	52.1		34	51.5	

expression both in the cancer cells ($p = 0.0008$) and the neighboring fibroblasts ($p = 0.0001$) negatively correlated with OS (Figure 3A and 3B). Tumor expression of MMP-13 negatively correlated with patients' OS regardless of the Her-2/neu status. It was noted that MMP-13 detected in peritumoral fibroblasts correlated with the OS of the lymph node positive subgroup ($p = 0.047$) and with the Her-2/neu negative subgroups ($p = 0.045$) (Figure 3C-F). When the patients' survival was stratified by lymph node status, MMP-13 expression was negatively correlated with the OS of the lymph node positive subgroups ($p = 0.0041$), but not with the OS of the lymph node negative subgroups ($p = 0.344$).

In the Cox regression model, univariate survival analyses showed that tumor size, lymph node positivity (>N2), PR,

Her-2/neu, TIMP-1 and MMP-13 were each associated with worse prognoses, while, multivariate survival analyses showed that lymph node positivity (>N2), tumor size, Her-2/neu, MMP-13 and TIMP-1 expression by cancer cells were independent adverse prognostic factors for overall survival (Table 4). Parallel analyses showed that ER and Tumor Grades were not correlated with OS.

Discussion

Predicting patients' prognoses is clearly one of the most challenging issues in breast cancer treatments. Racial, geographical and dietary factors have all been considered for their impacts on breast cancer incidences and survival. However, at the histopathological level, breast cancer is a highly heterogeneous disease, hampering the prognosis predictions. Histological grading, as shown by others and




Figure 2
Representative IHC of an infiltrating ductal carcinoma TMA. (A): MMP-2; **(B):** MMP-9; **(C):** TIMP-1; and **(D):** TIMP-2. The brown staining represents the indicated antigen, while blue color is the counterstain of the nuclei. $\times 400$.

data in this paper, is not a reliable prognostic predictors. To this end, hormone receptors (ER and PR) and Her-2/neu have been used with certain degrees of success as the biomarkers. In the current study, we examined a cohort of 263 Chinese breast cancer specimens and report the evidence that MMP-13 correlated with more aggressive breast cancer. Our data suggest that MMP13 may serve as a marker for poor prognoses. To our knowledge, this is the first IHC study to investigate the potential utility of MMP-13 as a biomarker of breast cancer among Chinese patients.

Our data support the earlier notion that MMP-13 marked the transition of ductal carcinoma *in situ* to invasive carcinomas [25] and increased the invasiveness of breast cancer cells *in vitro* [21]. The biological activity of MMP-13 in tumor progression may not be limited to breast cancer.

For instance, Culhaci N et al, showed a significant correlation of MMP-13 with the aggressiveness of head and neck squamous carcinomas [20].

Although tumor cells are the ones that pass through multiple tissue barriers to metastasize, increasing evidence demonstrates a critical role of stromal cells in tumor microenvironments [32,33]. Vizoso FJ noted that MMP-13 in fibroblastic cells and mononuclear immune cells was associated with increased risks of metastases [34]. Interestingly, others have reported that MMP-13 protein was restricted to small stromal foci within the tumor masses and was specifically produced by invading tumor cells [25]. In this study, we found MMP-13 protein in the cytoplasm of both cancer cells and tumor-adjacent fibroblasts. The expression of MMP-13 in cancer cells correlated with the MMP-13 expression in the peritumoral fibro-

Table 3: Correlation of MMP-13 expression with OS of overall and stratified subpopulations.

	MMP-13SI	Tumor				Stromal Fibroblast			
		n	E	OS (95% CI)	p	n	E	OS (95% CI)	p
Overall									
	Low	133	20	153 (145~161)	0.0008	132	20	153(145~161)	0.0001
	High	127	47	107 (98~116)		125	48	106 (97~115)	
Node Status									
Negative	Low	82	8	135 (128~142)	0.3442	70	6	137 (131~143)	0.1231
	High	43	7	122 (115~129)		55	10	128/(119~137)	
Positive	Low	50	12	142 (127~158)	0.0041	45	13	136 (118~153)	0.0494
	High	82	40	93 (80~105)		87	39	97 (85~108)	
HER2/neu									
Negative	Low	113	14	157 (149~165)	0.0092	106	15	155 (145~163)	0.0446
	High	93	25	120 (111~129)		100	25	121 (113~130)	
Positive	Low	19	6	109 (85~133)	0.0154	9	4	96 (58~133)	0.5278
	High	32	22	69 (50~88)		42	24	81 (64~98)	

OS: Months of overall survival; n: Number of patients; E: Events of positive stains; CI: confidence interval.

lasts. Furthermore, high levels of MMP-13 in cancer/peritumoral fibroblast cells correlated with tumor infiltration of lymph nodes. While this finding suggests that MMP-13 is likely to play a role in promoting tumor invasion and metastasis, future studies are needed to clarify whether the MMP-13 protein was expressed by both cancer cells and fibroblasts or by tumor cells alone.

The two types of most widely accepted prognostic biomarkers for breast cancer are hormone receptor (ER and/or PR) and oncoprotein Her-2/neu. ER is used to predict not only the response to endocrine therapy but also better overall survival. In contrast, Her-2/neu predicts more aggressive tumor phenotype, poor disease-free survival and poor OS [26,27]. High levels of MMP-13 in cancer cells correlated with the expression of the Her-2/neu protein. Recently, similar results were reported by Ocharonrat et al, with head and neck squamous cell carcinoma specimens [35]. Currently, it is not known whether MMP-13 is regulated by Her-2/neu. To this end, it is important to note that MMP-13 seems to be of prognostic value even for the Her-2/neu positive subset of cases, suggesting a Her-2/neu-independent function of MMP-13 in promoting breast cancer progression.

The correlation of MMP-13 with poor OS and tumor infiltration of lymph nodes suggests that it may promote tumor invasion. Since MMP-13 is a metalloproteinase, it may act in a similar manner as other MMPs, such as MMP-2, MMP-9. In fact, both MMP-2 and MMP-9 have been extensively studied as biomarkers and as well as therapeutic targets in breast cancer [36-39]. Interestingly, MMP-13 in both cancer cells and peritumoral fibroblast cells showed no correlation with either MMP-2 or MMP-9. Instead, we noted that MMP-13, both in cancer cells and

peritumoral fibroblast cells, correlated with TIMP-1 and TIMP-2 (to a lesser extent). Thus, MMP-13 may be independent of MMP-2 and MMP-9 as a marker as well as a regulator of breast tumor progression. The intricate interplays among MMPs and TIMPs could be more complex. Indeed, in contrast to the initial simple biochemistry-based hypothesis, TIMP-1 is viewed as a promising marker to predict poor prognoses of human breast cancer [40-42]. The recent discovery of proteolysis-independent biological functions of TIMPs, such as the growth-stimulating, anti-apoptotic and pro-angiogenic properties, provided new insights into this paradox [40-42]. Further studies are needed to clarify whether MMP-13 and TIMPs act as cognate partners or independent of each other.

Conclusion

This IHC study of TMA with 263 specimens of Chinese breast cancer provided the first evidence that MMP-13 is highly expressed by both the tumor cells and adjacent fibroblast cells. High levels of MMP-13 in these two tissue compartments were strongly correlated with each other, and further correlated with Her-2/neu, TIMP-1, lymph node metastasis and decreased overall survival. Our study suggests a potential application of MMP-13 as an independent biomarker for breast cancer prognosis.

Abbreviations

MMP: matrix metalloproteinase; TIMP: tissue inhibitor of matrix metalloproteinase; ER: Estrogen Receptors; PR: Progesterone Receptors; ECM: extracellular matrix; RFS: relapse-free survival; OS: Overall survival; SI: staining index




Figure 3

The prognostic significance of high MMP-13 protein expression in the entire patient population. The graphs show the effect of MMP-13 expression within cancer cells (**A**) and within peritumoral fibroblast cells (**B**) on patient overall survival (Log-rank test) and stratified analysis by lymph nodes status (**C & D**) and Her-2/neu status (**E & F**). Both high MMP-13 expression in cancer cells (**A**) and fibroblasts (**B**) associated with decreased overall survival ($p = 0.0008$ and 0.0001 , respectively). When patients' OS were stratified by lymph node status and Her-2/neu status, MMP-13 expression in cancer cells was associated with reduced OS in the Her-2/neu positive and negative (**E**, $p = 0.0092$ and $p = 0.0154$, respectively) and lymph node positive subgroups (**D**, $p = 0.0041$). However, MMP-13 expressed within fibroblasts only weakly affected OS of lymph node positive (**D**) and Her-2/neu negative subgroups (**F**, $p = 0.04694$ and 0.04461 , respectively)

Table 4: Univariate and multivariate Cox survival analysis

Variables	p	HR	OS (95% CI)
Univariate			
Menopausal Status	0.215	0.958	(0.772–1.188)
Tumor Size	0.029	1.569	(1.264–1.946)
Lymph Node Status	< 0.001	2.198	(1.860–2.596)
Histological Grade	0.045	1.438	(1.072–1.929)
ER	0.091	0.778	(0.579–1.042)
PR	0.046	0.687	(0.565–0.836)
Her-2/neu	< 0.001	1.989	(1.684–2.349)
High Tumor MMP-13	0.007	1.357	(1.171–1.571)
High Stromal Fibroblast MMP-13	0.146	0.995	(0.786–1.259)
High Tumor-derived MMP-2	0.443	1.276	(0.969–1.678)
High Tumor-derived MMP-9	0.889	1.245	(0.984–1.575)
High Tumor-derived TIMP-1	0.023	1.278	(1.103–1.480)
High Tumor-derived TIMP-2	0.881	1.072	(0.842–1.364)
Multivariate			
Histological Grade	0.041	1.441	(1.074–1.933)
Lymph Node Status	< 0.001	2.199	(1.861–2.598)
Her-2/neu	< 0.001	1.98	(1.685–2.350)
Tumor Size	0.024	1.570	(1.266–1.948)
High Tumor MMP-13	0.006	1.565	(1.178–1.581)
High Tumor TIMP-1	0.021	1.281	(1.106–1.484)

HR: Hazard Risk in Cox proportional hazard model analysis. HR>1.0 means positive correlation with risk. HR<1.0 means negative correlation with risk.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

ZB, CXC and ZF participated in the design of the study, optimized and carried out the immunohistochemical staining, performed the statistical analysis and drafted the manuscript. LHT and NLS collected the human tissue. LYX and CWF evaluated the results of immunohistochemical staining. ZSW and SBC prepared tumor tissue arrays block. FL and NY classified the invasive carcinomas. HXS and NRF participated in the design and the coordination of the study. All authors read and approved the final manuscript.

Acknowledgements

This study was supported by the Tianjin Medical University Cancer Institute and Hospital (TJMUCIH) Research Fund and the Tianjin Public Health Bureau (TJPHB) Research Fund.

References

1. Yu KD, Di GH, Wu J, Lu JS, Shen KW, Shen ZZ, Shao ZM: **Development and Trends of Surgical Modalities for Breast Cancer in China: A Review of 16-Year Data.** *Ann Surg Oncol* 2007, **14**:2502-2509.
2. Tavassoéli FA, Devilee P: **Pathology and Genetics: Tumors of the Breast and Female Genital.** Organs Lyon: WHO Press; IARC WHO Classification of Tumours, No. 4; 2003.
3. Choi DH, Shin DB, Lee MH, Lee DW, Dhandapani D, Carter D, King BL, Haffey BG: **A comparison of five immunohistochemical**

4. Freije JM, Díez-Itza I, Balbin M, Sánchez LM, Blasco R, Tolivia J, López-Otin C: **Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas.** *J Biol Chem* 1996, **49**:20-37.
5. Crawford HC, Matrisian LM: **Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells.** *Enzyme Protein* 1996, **49**:20-37.
6. Knäuper V, López-Otin C, Smith B, Knight G, Murphy G: **Biochemical characterization of human collagenase-3.** *J Biol Chem* 1996, **271**:1544-1550.
7. Ala-aho R, Kähäri VM: **Collagenases in cancer.** *Biochimie* 2005, **87**:273-86.
8. Leeman MF, Curran S, Murray GI: **The structure, regulation, and function of human matrix metalloproteinase-13.** *Crit Rev Biochem Mol Biol* 2002, **37**:149-166.
9. Pendas AM, Uria JA, Jimenez MG, Balbin M, Freije JP, Lopez-Otin C: **An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in anti-tumor therapies.** *Clin Chim Acta* 2000, **291**:137-155.
10. Balbin M, Pendas AM, Uria JA, Jimenez MG, Freije JP, Lopez-Otin C: **Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors.** *APMIS* 1999, **107**:45-53.
11. Corte MD, Gonzalez LO, Corte MG, Quintela I, Pidal I, Bongera M, Vizoso F: **Collagenase-3 (MMP-13) expression in cutaneous malignant melanoma.** *Int J Biol Markers* 2005, **20**:242-248.
12. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, Grénman R: **Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.** *Head Neck* 2006, **28**:225-234.
13. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI: **Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.** *Clin Cancer Res* 2004, **10**:8229-8234.
14. Dünne AA, Sesterhenn A, Gerisch A, Teymoortash A, Kuropkat C, Werner JA: **Expression of MMP-2, -9 and -13 in cell lines and fresh biopsies of squamous cell carcinomas of the upper aerodigestive tract.** *Anticancer Res* 2003, **23**:2233-2239.
15. Bartsch JE, Staren ED, Appert HE: **Matrix metalloproteinase expression in breast cancer.** *J Surg Res* 2003, **110**:383-392.
16. Leeman MF, McKay JA, Murray GI: **Matrix metalloproteinase 13 activity is associated with poor prognosis in colorectal cancer.** *J Clin Pathol* 2002, **55**:758-762.
17. Boström PJ, Ravanti L, Reunanen N, Aaltonen V, Söderström KO, Kähäri VM, Laato M: **Expression of collagenase-3 (matrix metalloproteinase-13) in transitional-cell carcinoma of the urinary bladder.** *Int J Cancer* 2000, **88**:417-423.
18. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, Grénman R: **Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer.** *Head Neck* 2006, **28**:225-234.
19. Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI: **Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.** *Clin Cancer Res* 2004, **10**:8229-8234.
20. Culhaci N, Metin K, Copcu E, Dikicioglu E: **Elevated expression of MMP-13 and TIMP-1 in head and neck squamous cell carcinomas may reflect increased tumor invasiveness.** *BMC Cancer* 2004, **4**:42.
21. Balduyck M, Zerimech F, Gouyer V, Lemaire R, Hemon B, Grard G, Thiebaut C, Lemaire V, Daquembronne E, Duhem T, Lebrun A, Dejonghe MJ, Huet G: **Specific expression of matrix metalloproteinases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro.** *Clin Exp Metastasis* 2000, **18**:171-178.
22. Daja MM, Niu X, Zhao Z, Brown JM, Russell PJ: **Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines.** *Prostate Cancer Prostatic Dis* 2003, **6**:15-26.
23. Airola K, Karonen T, Vaalamo M, Lehti K, Lohi J, Kariniemi AL, Keski-Oja J, Saarialho-Kere UK: **Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.** *Br J Cancer* 1999, **80**:733-743.

24. Johansson N, Vaalamo M, Grénman S, Hietanen S, Klemi P, Saarialho-Kere U, Kähäri VM: **Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas.** *Am J Pathol* 1999, **154**:469-480.
25. Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano K, Lopez-Otin C: **Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas.** *Cancer Res* 2001, **61**:7091-7100.
26. Engelholm LH, Nielsen BS, Netzel-Arnett S, Solberg H, Chen XD, Lopez Garcia JM, Lopez-Otin C, Young MF, Birkedal-Hansen H, DanÅ K, Lund LR, Behrendt N, Bugge TH: **The urokinase plasminogen activator receptor-associated protein/endo180 is coexpressed with its interaction partners urokinase plasminogen activator receptor and matrix metalloproteinase-13 during osteogenesis.** *Lab Invest* 2005, **81**:1403-14.
27. Cao WF, Zhang B, Liu YX: **SLP-2 high expression associated with HER2/neu protein expression decreased breast cancer patient survival.** *Am J Clin Pathol* 2007, **128**:430-436.
28. Riley SC, Leask R, Denison FC, Wisely K, Calder AA, Howe DC: **Secretion of tissue inhibitors of matrix metalloproteinases by human fetal membranes, decidua and placenta at parturition.** *J Endocrinol* 1999, **162**:351-359.
29. Demir-Weusten AY, Seval Y, Kaufmann P, Demir R, Yucel G, Hupertz B: **Matrix metalloproteinases-2, -3 and -9 in human term placenta.** *Acta Histochem* 2007, **109**:403-412.
30. Takai N, Jain A, Kawamata N, Popoviciu LM, Said JW, Whittaker S, Miyakawa I, Agus DB, Koeffler HP: **2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.** *Cancer* 2005, **104**:2701-2708.
31. Carlson RW, Moench SJ, Hammond EH, Perez EA, Burstein HJ, Allred C, Vogel CL, Goldstein LJ, Somio G, Gradishar WJ: **HER2 testing in breast cancer: NCCN task force report and recommendations.** *J Natl Compr Canc Netw* 2006, **4**(Suppl 3):S1-S22. quiz S23-S24
32. O-Charoenrat P, Rhys-Evans PH, Eccles SA: **Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck.** *Arch Otolaryngol Head Neck Surg* 2001, **127**:813-820.
33. Charous SJ, Stricklin GP, Nanney LB, Nettekville JL, Burkey BB: **Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in head and neck squamous cell carcinoma.** *Ann Otol Rhinol Laryngol* 1997, **106**:271-278.
34. Vizoso FJ, Gonzalez LO, Corte MD, Rodriguez JC, Vazquez J, Lamelas ML, Junquera S, Merino AM, Garcia-Muniz JL: **Study of matrix metalloproteinase and their inhibitors in breast cancer.** *Br J Cancer* 2007, **96**:903-11.
35. O-charoenrat P, Rhys-Evans PH, Archer DJ, Eccles SA: **C-erbB receptors in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinase and vascular endothelial growth factors.** *Oral Oncol* 2002, **38**:73-80.
36. Jinga DC, Blidaru A, Condrea I, Ardeleanu C, Dragomir C, Szegli G, Stefanescu M, Matache C: **MMP-9 and MMP-2 gelatinases and TIMP-1 and TIMP-2 inhibitors in breast cancer: correlations with prognostic factors.** *J Cell Mol Med* 2006, **10**:499-510.
37. Kuvaja P, Talvensaar-Mattila A, Paakko P, Turpeenniemi-Hujanen T: **The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.** *Oncology* 2005, **68**:196-203.
38. Li HC, Cao DC, Liu Y, Hou YF, Wu J, Lu JS, Di GH, Liu G, Li FM, Ou ZL, Jie C, Shen ZZ, Shao ZM: **Prognostic value of matrix metalloproteinase (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma.** *Breast Cancer Res Treat* 2004, **88**:75-85.
39. Tetu B, Brisson J, Wang CS, Lapointe H, Beaudry G, Blanchette C, Trudel D: **The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis.** *Breast Cancer Res* 2006, **8**:R28.
40. Hornebeck W, Lambert E, Petitfrere E, Bernard P: **Beneficial and detrimental influences of tissue inhibitor of metalloproteinase-1 (TIMP-1) in tumor progression.** *Biochimie* 2005, **87**:377-83.
41. Liu SC, Yang SF, Yeh KT, Yeh CM, Chiou HL, Lee CY, Chou MC, Hsieh YS: **Relationships between the level of matrix metalloproteinase-2 and tumor size of breast cancer.** *Clin Chim Acta* 2006, **371**:92-96.
42. Wurtz SO, Schroll AS, Sorensen NM, Lademann U, Christensen IJ, Mouridsen H, Brunner N: **Tissue inhibitor of metalloproteinases-1 in breast cancer.** *Endocr Relat Cancer* 2005, **12**:215-27.

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/8/83/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

